According to a newly-amended 13D filing with the SEC, Jeffrey Smith‘s Starboard Value LP owns 5.64 million shares of Depomed Inc (NASDAQ:DEPO), which account for 9.2% of the company’s outstanding stock. Mr. Smith’s firm has added about 1.50 million shares to its position since it reported a holding of 4.14 million shares in a previous 13D filing. In that previous filing, the activist investor also voiced concerns about the board’s intention to strengthen itself, saying that it should instead be focused on working constructively with shareholders to increase shareholder value. Given that, Starboard Value LP revealed that it will recommend one or more candidates for the position of Director on the company’s board.
Among the funds tracked by Insider Monkey, at the end the December a total of 23 hedge funds were bullish on this stock. Richard Mashaal’s RIMA Senvest Management held the most valuable position in Depomed Inc (NASDAQ:DEPO), which was worth $74 million. Coming in second was Kevin Kotler’s Broadfin Capital, which reported a $13.2 million position in its latest 13F filing. Other investors that held long positions were Matthew Mark’s Jet Capital Investors, Paul Sinclair’s Blue Jay Capital Management, and Joseph Edelman’s Perceptive Advisors.
On the other hand, Carl Tiedemann and Michael Tiedemann’s TIG Advisors dumped the largest investment among the firms that we track, valued at close to $48.5 million in stock, followed by Thomas Steyer’s fund, Farallon Capital, which dumped about $30.3 million worth of shares. Total hedge fund interest in Depomed Inc (NASDAQ:DEPO) dropped by nine funds in the fourth quarter.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| STARBOARD VALUE | 5,640,000 | 5,640,000 | 5,640,000 | 5,640,000 | 5,640,000 | 9.2% |
| STARBOARD VALUE AND OPPORTUNITY MASTER FUND LTD | 4,346,917 | 5,640,000 | 4,346,917 | 5,640,000 | 4,346,917 | 7.1% |
| STARBOARD VALUE AND OPPORTUNITY S | 514,482 | 5,640,000 | 514,482 | 5,640,000 | 514,482 | Less than 1% |
| STARBOARD VALUE AND OPPORTUNITY C | 285,827 | 285,827 | 285,827 | Less than 1% | ||
| STARBOARD VALUE R | 285,827 | 285,827 | 285,827 | Less than 1% | ||
| STARBOARD VALUE R GP | 285,827 | 285,827 | 285,827 | Less than 1% | ||
| STARBOARD VALUE GP | 5,640,000 | 5,640,000 | 5,640,000 | 9.2% | ||
| STARBOARD PRINCIPAL CO | 5,640,000 | 5,640,000 | 5,640,000 | 9.2% | ||
| STARBOARD PRINCIPAL CO GP | 5,640,000 | 5,640,000 | 5,640,000 | 9.2% | ||
| JEFFREY C. SMITH | 16,450 | 16,450 | 5,640,000 | 9.2% | ||
| MARK R. MITCHELL | 5,640,000 | 9.2% | ||||
| PETER A. FELD | 5,640,000 | 9.2% | ||||
| GAVIN T. MOLINELLI | 16,450 | 0% | ||||
| PATRICK SULLIVAN | 0% | |||||
| JAMES P. FOGARTY | Less than 1% |
Follow Jeff Smith's Starboard Value LP
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 26 – SEC Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
§ 240.13d-2(a)
(Amendment No. 1)1
Depomed, Inc.
(Name of Issuer)
Common Stock, no par value
(Title of Class of Securities)
249908104
(CUSIP Number)
JEFFREY C. SMITH
STARBOARD VALUE LP
777 Third Avenue, 18th Floor
New York, New York 10017
(212) 845-7977
STEVE WOLOSKY, ESQ.
OLSHAN FROME WOLOSKY LLP
Park Avenue Tower
65 East 55th Street
New York, New York 10022
(212) 451-2300
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
April 8, 2016
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.
_______________
1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 2 of 26 – SEC Filing
| 1 | NAME OF REPORTING PERSON STARBOARD VALUE LP | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) o | |
| 3 | SEC USE ONLY | ||
| 4 | SOURCE OF FUNDS OO | ||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ¨ | |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 5,640,000 | |
| 8 | SHARED VOTING POWER – 0 – | ||
| 9 | SOLE DISPOSITIVE POWER 5,640,000 | ||
| 10 | SHARED DISPOSITIVE POWER – 0 – | ||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,640,000 | ||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | o | |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 9.2%* | ||
| 14 | TYPE OF REPORTING PERSON PN | ||
* Possesses economic exposure to an aggregate of 6,015,000 shares (representing approximately 9.9% of the outstanding shares) due to certain cash-settled total return swap agreements as further explained in Item 6.
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 3 of 26 – SEC Filing
| 1 | NAME OF REPORTING PERSON STARBOARD VALUE AND OPPORTUNITY MASTER FUND LTD | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) o | |
| 3 | SEC USE ONLY | ||
| 4 | SOURCE OF FUNDS WC | ||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ¨ | |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION CAYMAN ISLANDS | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 4,346,917 | |
| 8 | SHARED VOTING POWER – 0 – | ||
| 9 | SOLE DISPOSITIVE POWER 4,346,917 | ||
| 10 | SHARED DISPOSITIVE POWER – 0 – | ||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,346,917 | ||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | o | |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 7.1%* | ||
| 14 | TYPE OF REPORTING PERSON CO | ||
* Possesses economic exposure to an aggregate of 4,636,387 shares (representing approximately 7.6% of the outstanding shares) due to certain cash-settled total return swap agreements as further explained in Item 6.
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 4 of 26 – SEC Filing
| 1 | NAME OF REPORTING PERSON STARBOARD VALUE AND OPPORTUNITY S LLC | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) o | |
| 3 | SEC USE ONLY | ||
| 4 | SOURCE OF FUNDS WC | ||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ¨ | |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 514,482 | |
| 8 | SHARED VOTING POWER – 0 – | ||
| 9 | SOLE DISPOSITIVE POWER 514,482 | ||
| 10 | SHARED DISPOSITIVE POWER – 0 – | ||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 514,482 | ||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | o | |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) Less than 1%* | ||
| 14 | TYPE OF REPORTING PERSON OO | ||
* Possesses economic exposure to an aggregate of 548,714 shares (representing less than 1% of the outstanding shares) due to certain cash-settled total return swap agreements as further explained in Item 6.
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 5 of 26 – SEC Filing
| 1 | NAME OF REPORTING PERSON STARBOARD VALUE AND OPPORTUNITY C LP | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) o | |
| 3 | SEC USE ONLY | ||
| 4 | SOURCE OF FUNDS WC | ||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ¨ | |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 285,827 | |
| 8 | SHARED VOTING POWER – 0 – | ||
| 9 | SOLE DISPOSITIVE POWER 285,827 | ||
| 10 | SHARED DISPOSITIVE POWER – 0 – | ||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 285,827 | ||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | o | |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) Less than 1%* | ||
| 14 | TYPE OF REPORTING PERSON PN | ||
* Possesses economic exposure to an aggregate of 304,821 shares (representing less than 1% of the outstanding shares) due to certain cash-settled total return swap agreements as further explained in Item 6.
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 6 of 26 – SEC Filing
| 1 | NAME OF REPORTING PERSON STARBOARD VALUE R LP | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) o | |
| 3 | SEC USE ONLY | ||
| 4 | SOURCE OF FUNDS OO | ||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ¨ | |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 285,827 | |
| 8 | SHARED VOTING POWER – 0 – | ||
| 9 | SOLE DISPOSITIVE POWER 285,827 | ||
| 10 | SHARED DISPOSITIVE POWER – 0 – | ||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 285,827 | ||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | o | |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) Less than 1%* | ||
| 14 | TYPE OF REPORTING PERSON PN | ||
* Possesses economic exposure to an aggregate of 304,821 shares (representing less than 1% of the outstanding shares) due to certain cash-settled total return swap agreements as further explained in Item 6.
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 7 of 26 – SEC Filing
| 1 | NAME OF REPORTING PERSON STARBOARD VALUE R GP LLC | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) o | |
| 3 | SEC USE ONLY | ||
| 4 | SOURCE OF FUNDS OO | ||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ¨ | |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 285,827 | |
| 8 | SHARED VOTING POWER – 0 – | ||
| 9 | SOLE DISPOSITIVE POWER 285,827 | ||
| 10 | SHARED DISPOSITIVE POWER – 0 – | ||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 285,827 | ||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | o | |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) Less than 1%* | ||
| 14 | TYPE OF REPORTING PERSON OO | ||
* Possesses economic exposure to an aggregate of 304,821 shares (representing less than 1% of the outstanding shares) due to certain cash-settled total return swap agreements as further explained in Item 6.
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 8 of 26 – SEC Filing
| 1 | NAME OF REPORTING PERSON STARBOARD VALUE GP LLC | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) o | |
| 3 | SEC USE ONLY | ||
| 4 | SOURCE OF FUNDS OO | ||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ¨ | |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 5,640,000 | |
| 8 | SHARED VOTING POWER – 0 – | ||
| 9 | SOLE DISPOSITIVE POWER 5,640,000 | ||
| 10 | SHARED DISPOSITIVE POWER – 0 – | ||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,640,000 | ||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | o | |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 9.2%* | ||
| 14 | TYPE OF REPORTING PERSON OO | ||
* Possesses economic exposure to an aggregate of 6,015,000 shares (representing approximately 9.9% of the outstanding shares) due to certain cash-settled total return swap agreements as further explained in Item 6.
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 9 of 26 – SEC Filing
| 1 | NAME OF REPORTING PERSON STARBOARD PRINCIPAL CO LP | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) o | |
| 3 | SEC USE ONLY | ||
| 4 | SOURCE OF FUNDS OO | ||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ¨ | |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 5,640,000 | |
| 8 | SHARED VOTING POWER – 0 – | ||
| 9 | SOLE DISPOSITIVE POWER 5,640,000 | ||
| 10 | SHARED DISPOSITIVE POWER – 0 – | ||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,640,000 | ||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | o | |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 9.2%* | ||
| 14 | TYPE OF REPORTING PERSON PN | ||
* Possesses economic exposure to an aggregate of 6,015,000 shares (representing approximately 9.9% of the outstanding shares) due to certain cash-settled total return swap agreements as further explained in Item 6.
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 10 of 26 – SEC Filing
| 1 | NAME OF REPORTING PERSON STARBOARD PRINCIPAL CO GP LLC | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) o | |
| 3 | SEC USE ONLY | ||
| 4 | SOURCE OF FUNDS OO | ||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ¨ | |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 5,640,000 | |
| 8 | SHARED VOTING POWER – 0 – | ||
| 9 | SOLE DISPOSITIVE POWER 5,640,000 | ||
| 10 | SHARED DISPOSITIVE POWER – 0 – | ||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,640,000 | ||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | o | |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 9.2%* | ||
| 14 | TYPE OF REPORTING PERSON OO | ||
* Possesses economic exposure to an aggregate of 6,015,000 shares (representing approximately 9.9% of the outstanding shares) due to certain cash-settled total return swap agreements as further explained in Item 6.
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 11 of 26 – SEC Filing
| 1 | NAME OF REPORTING PERSON JEFFREY C. SMITH | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) o | |
| 3 | SEC USE ONLY | ||
| 4 | SOURCE OF FUNDS OO | ||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ¨ | |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION USA | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER – 0 – | |
| 8 | SHARED VOTING POWER 5,640,000 | ||
| 9 | SOLE DISPOSITIVE POWER – 0 – | ||
| 10 | SHARED DISPOSITIVE POWER 5,640,000 | ||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,640,000 | ||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | o | |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 9.2%* | ||
| 14 | TYPE OF REPORTING PERSON IN | ||
* Possesses economic exposure to an aggregate of 6,015,000 shares (representing approximately 9.9% of the outstanding shares) due to certain cash-settled total return swap agreements as further explained in Item 6.
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 12 of 26 – SEC Filing
| 1 | NAME OF REPORTING PERSON MARK R. MITCHELL | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) o | |
| 3 | SEC USE ONLY | ||
| 4 | SOURCE OF FUNDS OO | ||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ¨ | |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION USA | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER – 0 – | |
| 8 | SHARED VOTING POWER 5,640,000 | ||
| 9 | SOLE DISPOSITIVE POWER – 0 – | ||
| 10 | SHARED DISPOSITIVE POWER 5,640,000 | ||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,640,000 | ||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | o | |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 9.2%* | ||
| 14 | TYPE OF REPORTING PERSON IN | ||
* Possesses economic exposure to an aggregate of 6,015,000 shares (representing approximately 9.9% of the outstanding shares) due to certain cash-settled total return swap agreements as further explained in Item 6.
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 13 of 26 – SEC Filing
| 1 | NAME OF REPORTING PERSON PETER A. FELD | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) o | |
| 3 | SEC USE ONLY | ||
| 4 | SOURCE OF FUNDS OO | ||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ¨ | |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION USA | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER – 0 – | |
| 8 | SHARED VOTING POWER 5,640,000 | ||
| 9 | SOLE DISPOSITIVE POWER – 0 – | ||
| 10 | SHARED DISPOSITIVE POWER 5,640,000 | ||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,640,000 | ||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | o | |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 9.2%* | ||
| 14 | TYPE OF REPORTING PERSON IN | ||
* Possesses economic exposure to an aggregate of 6,015,000 shares (representing approximately 9.9% of the outstanding shares) due to certain cash-settled total return swap agreements as further explained in Item 6.
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 14 of 26 – SEC Filing
| 1 | NAME OF REPORTING PERSON GAVIN T. MOLINELLI | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) o | |
| 3 | SEC USE ONLY | ||
| 4 | SOURCE OF FUNDS | ||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ¨ | |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION USA | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER – 0 – | |
| 8 | SHARED VOTING POWER – 0 – | ||
| 9 | SOLE DISPOSITIVE POWER – 0 – | ||
| 10 | SHARED DISPOSITIVE POWER – 0 – | ||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON – 0 – | ||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | o | |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0% | ||
| 14 | TYPE OF REPORTING PERSON IN | ||
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 15 of 26 – SEC Filing
| 1 | NAME OF REPORTING PERSON PATRICK SULLIVAN | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) o | |
| 3 | SEC USE ONLY | ||
| 4 | SOURCE OF FUNDS | ||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ¨ | |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION USA | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER – 0 – | |
| 8 | SHARED VOTING POWER – 0 – | ||
| 9 | SOLE DISPOSITIVE POWER – 0 – | ||
| 10 | SHARED DISPOSITIVE POWER – 0 – | ||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON – 0 – | ||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | o | |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0% | ||
| 14 | TYPE OF REPORTING PERSON IN | ||
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 16 of 26 – SEC Filing
| 1 | NAME OF REPORTING PERSON JAMES P. FOGARTY | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) o | |
| 3 | SEC USE ONLY | ||
| 4 | SOURCE OF FUNDS PF | ||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ¨ | |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION USA | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 16,450 | |
| 8 | SHARED VOTING POWER – 0 – | ||
| 9 | SOLE DISPOSITIVE POWER 16,450 | ||
| 10 | SHARED DISPOSITIVE POWER – 0 – | ||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 16,450 | ||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | o | |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) Less than 1% | ||
| 14 | TYPE OF REPORTING PERSON IN | ||
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 17 of 26 – SEC Filing
The following constitutes Amendment No. 1 to the Schedule 13D filed by the undersigned (“Amendment No. 1”). This Amendment No. 1 amends the Schedule 13D as specifically set forth herein.
| Item 3. | Source and Amount of Funds or Other Consideration. |
Item 3 is hereby amended and restated to read as follows:
The Shares purchased by each of Starboard V&O Fund, Starboard S LLC and Starboard C LP and held in the Starboard Value LP Account were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business) in open market purchases, except as otherwise noted, as set forth in Schedule A, which is incorporated by reference herein. The aggregate purchase price of the 4,346,917 Shares beneficially owned by Starboard V&O Fund is approximately $64,864,508, excluding brokerage commissions. The aggregate purchase price of the 514,482 Shares beneficially owned by Starboard S LLC is approximately $7,712,247, excluding brokerage commissions. The aggregate purchase price of the 285,827 Shares beneficially owned by Starboard C LP is approximately $4,264,708, excluding brokerage commissions. The aggregate purchase price of the 492,774 Shares held in the Starboard Value LP Account is approximately $7,379,301, excluding brokerage commissions.
The Shares owned directly by Mr. Fogarty were purchased with personal funds in open market purchases. The aggregate purchase price of the 16,450 Shares directly owned by Mr. Fogarty is approximately $249,711, excluding brokerage commissions.
| Item 5. | Interest in Securities of the Issuer. |
Items 5(a) – (c) are hereby amended and restated to read as follows:
The aggregate percentage of Shares reported owned by each person named herein is based upon 60,994,669 Shares outstanding, as of March 31, 2016, which is the total number of Shares outstanding as reported in the Issuer’s Preliminary Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 5, 2016.
| A. | Starboard V&O Fund |
| | (a) | As of the close of business on April 12, 2016, Starboard V&O Fund beneficially owned 4,346,917 Shares. |
Percentage: Approximately 7.1%
| | (b) | 1. Sole power to vote or direct vote: 4,346,917 |
| | 2. Shared power to vote or direct vote: 0 |
| | 3. Sole power to dispose or direct the disposition: 4,346,917 |
| | 4. Shared power to dispose or direct the disposition: 0 |
| | (c) | The transactions in the Shares by Starboard V&O Fund since the filing of the Schedule 13D are set forth in Schedule A and are incorporated herein by reference. |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 18 of 26 – SEC Filing
| B. | Starboard S LLC |
| | (a) | As of the close of business on April 12, 2016, Starboard S LLC beneficially owned 514,482 Shares. |
Percentage: Less than 1%
| | (b) | 1. Sole power to vote or direct vote: 514,482 |
| | 2. Shared power to vote or direct vote: 0 |
| | 3. Sole power to dispose or direct the disposition: 514,482 |
| | 4. Shared power to dispose or direct the disposition: 0 |
| | (c) | The transactions in the Shares by Starboard S LLC since the filing of the Schedule 13D are set forth in Schedule A and are incorporated herein by reference. |
| C. | Starboard C LP |
| | (a) | As of the close of business on April 12, 2016, Starboard C LP beneficially owned 285,827 Shares. |
Percentage: Less than 1%
| | (b) | 1. Sole power to vote or direct vote: 285,827 |
| | 2. Shared power to vote or direct vote: 0 |
| | 3. Sole power to dispose or direct the disposition: 285,827 |
| | 4. Shared power to dispose or direct the disposition: 0 |
| | (c) | The transactions in the Shares by Starboard C LP since the filing of the Schedule 13D are set forth in Schedule A and are incorporated herein by reference. |
| D. | Starboard R LP |
| | (a) | Starboard R LP, as the general partner of Starboard C LP, may be deemed the beneficial owner of the 285,827 shares owned by Starboard C LP. |
Percentage: Less than 1%
| | (b) | 1. Sole power to vote or direct vote: 285,827 |
| | 2. Shared power to vote or direct vote: 0 |
| | 3. Sole power to dispose or direct the disposition: 285,827 |
| | 4. Shared power to dispose or direct the disposition: 0 |
| | (c) | Starboard R LP has not entered into any transactions in the Shares since the filing of the Schedule 13D. The transactions in the Shares on behalf of Starboard C LP since the filing of the Schedule 13D are set forth in Schedule A and are incorporated herein by reference. |
| E. | Starboard R GP |
| | (a) | Starboard R GP, as the general partner of Starboard R LP, may be deemed the beneficial owner of the 285,827 shares owned by Starboard C LP. |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 19 of 26 – SEC Filing
Percentage: Less than 1%
| | (b) | 1. Sole power to vote or direct vote: 285,827 |
| | 2. Shared power to vote or direct vote: 0 |
| | 3. Sole power to dispose or direct the disposition: 285,827 |
| | 4. Shared power to dispose or direct the disposition: 0 |
| | (c) | Starboard R GP has not entered into any transactions in the Shares since the filing of the Schedule 13D. The transactions in the Shares on behalf of Starboard C LP since the filing of the Schedule 13D are set forth in Schedule A and are incorporated herein by reference. |
| F. | Starboard Value LP |
| | (a) | As of the close of business on April 12, 2016, 492,774 Shares were held in the Starboard Value LP Account. Starboard Value LP, as the investment manager of Starboard V&O Fund, Starboard C LP and the Starboard Value LP Account and the manager of Starboard S LLC, may be deemed the beneficial owner of the (i) 4,346,917 Shares owned by Starboard V&O Fund, (ii) 514,482 Shares owned by Starboard S LLC, (iii) 285,827 Shares owned by Starboard C LP, and (iv) 492,774 Shares held in the Starboard Value LP Account. |
Percentage: Approximately 9.2%
| | (b) | 1. Sole power to vote or direct vote: 5,640,000 |
| | 2. Shared power to vote or direct vote: 0 |
| | 3. Sole power to dispose or direct the disposition: 5,640,000 |
| | 4. Shared power to dispose or direct the disposition: 0 |
| | (c) | The transactions in the Shares by Starboard Value LP through the Starboard Value LP Account and on behalf of each of Starboard V&O Fund, Starboard S LLC and Starboard C LP since the filing of the Schedule 13D are set forth in Schedule A and are incorporated herein by reference. |
| G. | Starboard Value GP |
| | (a) | Starboard Value GP, as the general partner of Starboard Value LP, may be deemed the beneficial owner of the (i) 4,346,917 Shares owned by Starboard V&O Fund, (ii) 514,482 Shares owned by Starboard S LLC, (iii) 285,827 Shares owned by Starboard C LP, and (iv) 492,774 Shares held in the Starboard Value LP Account. |
Percentage: Approximately 9.2%
| | (b) | 1. Sole power to vote or direct vote: 5,640,000 |
| | 2. Shared power to vote or direct vote: 0 |
| | 3. Sole power to dispose or direct the disposition: 5,640,000 |
| | 4. Shared power to dispose or direct the disposition: 0 |
| | (c) | Starboard Value GP has not entered into any transactions in the Shares since the filing of the Schedule 13D. The transactions in the Shares on behalf of each of Starboard V&O Fund, Starboard S LLC, Starboard C LP and through the Starboard Value LP Account since the filing of the Schedule 13D are set forth in Schedule A and are incorporated herein by reference. |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 20 of 26 – SEC Filing
| H. | Principal Co |
| | (a) | Principal Co, as a member of Starboard Value GP, may be deemed the beneficial owner of the (i) 4,346,917 Shares owned by Starboard V&O Fund, (ii) 514,482 Shares owned by Starboard S LLC, (iii) 285,827 Shares owned by Starboard C LP, and (iv) 492,774 Shares held in the Starboard Value LP Account. |
Percentage: Approximately 9.2%
| | (b) | 1. Sole power to vote or direct vote: 5,640,000 |
| | 2. Shared power to vote or direct vote: 0 |
| | 3. Sole power to dispose or direct the disposition: 5,640,000 |
| | 4. Shared power to dispose or direct the disposition: 0 |
| | (c) | Principal Co has not entered into any transactions in the Shares since the filing of the Schedule 13D. The transactions in the Shares on behalf of each of Starboard V&O Fund, Starboard S LLC, Starboard C LP and through the Starboard Value LP Account since the filing of the Schedule 13D are set forth in Schedule A and are incorporated herein by reference. |
| I. | Principal GP |
| | (a) | Principal GP, as the general partner of Principal Co, may be deemed the beneficial owner of the (i) 4,346,917 Shares owned by Starboard V&O Fund, (ii) 514,482 Shares owned by Starboard S LLC, (iii) 285,827 Shares owned by Starboard C LP, and (iv) 492,774 Shares held in the Starboard Value LP Account. |
Percentage: Approximately 9.2%
| | (b) | 1. Sole power to vote or direct vote: 5,640,000 |
| | 2. Shared power to vote or direct vote: 0 |
| | 3. Sole power to dispose or direct the disposition: 5,640,000 |
| | 4. Shared power to dispose or direct the disposition: 0 |
| | (c) | Principal GP has not entered into any transactions in the Shares since the filing of the Schedule 13D. The transactions in the Shares on behalf of each of Starboard V&O Fund, Starboard S LLC, Starboard C LP and through the Starboard Value LP Account since the filing of the Schedule 13D are set forth in Schedule A and are incorporated herein by reference. |
| J. | Messrs. Smith, Mitchell and Feld |
| | (a) | Each of Messrs. Smith, Mitchell and Feld, as a member of Principal GP and as a member of each of the Management Committee of Starboard Value GP and the Management Committee of Principal GP, may be deemed the beneficial owner of the (i) 4,346,917 Shares owned by Starboard V&O Fund, (ii) 514,482 Shares owned by Starboard S LLC, (iii) 285,827 Shares owned by Starboard C LP, and (iv) 492,774 Shares held in the Starboard Value LP Account. |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 21 of 26 – SEC Filing
Percentage: Approximately 9.2%
| | (b) | 1. Sole power to vote or direct vote: 0 |
| | 2. Shared power to vote or direct vote: 5,640,000 |
| | 3. Sole power to dispose or direct the disposition: 0 |
| | 4. Shared power to dispose or direct the disposition: 5,640,000 |
| | (c) | None of Messrs. Smith, Mitchell or Feld has entered into any transactions in the Shares since the filing of the Schedule 13D. The transactions in the Shares on behalf of each of Starboard V&O Fund, Starboard S LLC, Starboard C LP and through the Starboard Value LP Account since the filing of the Schedule 13D are set forth in Schedule A and are incorporated herein by reference. |
| K. | Messrs. Molinelli and Sullivan |
| | (a) | As of the close of business on April 12, 2016, neither of Messrs. Molinelli or Sullivan owned any Shares. |
Percentage: 0%
| | (b) | 1. Sole power to vote or direct vote: 0 |
| | 2. Shared power to vote or direct vote: 0 |
| | 3. Sole power to dispose or direct the disposition: 0 |
| | 4. Shared power to dispose or direct the disposition: 0 |
| | (c) | Neither of Messrs. Molinelli or Sullivan has entered into any transactions in the Shares since the filing of the Schedule 13D. |
| L. | Mr. Fogarty |
| | (a) | As of the close of business on April 12, 2016, Mr. Fogarty directly owned 16,450 Shares. |
Percentage: Less than 1%
| | (b) | 1. Sole power to vote or direct vote: 16,450 |
| | 2. Shared power to vote or direct vote: 0 |
| | 3. Sole power to dispose or direct the disposition: 16,450 |
| | 4. Shared power to dispose or direct the disposition: 0 |
| | (c) | The transaction in the Shares by Mr. Fogarty since the filing of the Schedule 13D is set forth in Schedule A and is incorporated herein by reference. |
Each Reporting Person, as a member of a “group” with the other Reporting Persons for the purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, may be deemed the beneficial owner of the Shares directly owned by the other Reporting Persons. Each Reporting Person disclaims beneficial ownership of such Shares except to the extent of his or its pecuniary interest therein.
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 22 of 26 – SEC Filing
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer. |
Item 6 is hereby amended and restated to read as follows:
Starboard V&O Fund has entered into certain cash-settled total return swap agreements with Société Générale (“SG”) as the counterparty (the “Swap Agreements”). The swaps with SG constitute economic exposure to an aggregate of 289,470 notional Shares, representing less than 1% of the outstanding Shares, which have a maturity date of September 19, 2017. The Swap Agreements provide Starboard V&O Fund with economic results that are comparable to the economic results of ownership but do not provide it with the power to vote or direct the voting or dispose of or direct the disposition of the Shares that are the subject of the Swap Agreements (such shares, the “Subject Shares”). Taking into account the Subject Shares, Starboard V&O Fund has economic exposure to an aggregate of 4,636,387 Shares, representing approximately 7.6% of the outstanding Shares.
Starboard S LLC has entered into certain cash-settled total return swap agreements with SG as the counterparty. The swaps with SG constitute economic exposure to an aggregate of 34,232 notional Shares, representing less than 1% of the outstanding Shares, which have a maturity date of September 19, 2017. The Swap Agreements provide Starboard S LLC with economic results that are comparable to the economic results of ownership but do not provide it with the power to vote or direct the voting or dispose of or direct the disposition of the Shares that are the subject of the Swap Agreements (such shares, the “Subject Shares”). Taking into account the Subject Shares, Starboard S LLC has economic exposure to an aggregate of 548,714 Shares, representing less than 1% of the outstanding Shares.
Starboard C LP has entered into certain cash-settled total return swap agreements with SG as the counterparty. The swaps with SG constitute economic exposure to an aggregate of 18,994 notional Shares, representing less than 1% of the outstanding Shares, which have a maturity date of September 19, 2017. The Swap Agreements provide Starboard C LP with economic results that are comparable to the economic results of ownership but do not provide it with the power to vote or direct the voting or dispose of or direct the disposition of the Shares that are the subject of the Swap Agreements (such shares, the “Subject Shares”). Taking into account the Subject Shares, Starboard C LP has economic exposure to an aggregate of 304,821 Shares, representing less than 1% of the outstanding Shares.
Starboard Value LP through the Starboard Value LP Account has entered into certain cash-settled total return swap agreements with SG as the counterparty. The swaps with SG constitute economic exposure to an aggregate of 32,304 notional Shares, representing less than 1% of the outstanding Shares, which have a maturity date of September 19, 2017. The Swap Agreements provide Starboard Value LP with economic results that are comparable to the economic results of ownership but do not provide it with the power to vote or direct the voting or dispose of or direct the disposition of the Shares that are the subject of the Swap Agreements (such shares, the “Subject Shares”). Taking into account the Subject Shares, Starboard Value LP through the Starboard Value LP Account has economic exposure to an aggregate of 525,078 Shares, representing less than 1% of the outstanding Shares.
The Swap Agreements with SG referenced herein provide for various execution prices. Please refer to Schedule B of the Schedule 13D and Schedule A of any amendments thereto for the specific execution prices of the various swaps.
The Reporting Persons collectively have economic exposure to an aggregate of 6,031,450 Shares, representing approximately 9.9% of the outstanding Shares.
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 23 of 26 – SEC Filing
SIGNATURES
After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
Dated: April 12, 2016
| STARBOARD VALUE AND OPPORTUNITY MASTER FUND LTD By: Starboard Value LP, its investment manager STARBOARD VALUE AND OPPORTUNITY S LLC By: Starboard Value LP, its manager STARBOARD VALUE AND OPPORTUNITY C LP By: Starboard Value R LP, its general partner STARBOARD VALUE R LP By: Starboard Value R GP LLC, its general partner STARBOARD VALUE LP By: Starboard Value GP LLC, its general partner | STARBOARD VALUE GP LLC By: Starboard Principal Co LP, its member STARBOARD PRINCIPAL CO LP By: Starboard Principal Co GP LLC, its general partner STARBOARD PRINCIPAL CO GP LLC STARBOARD VALUE R GP LLC |
| By: | /s/ Jeffrey C. Smith | |
| Name: | Jeffrey C. Smith | |
| Title: | Authorized Signatory | |
| /s/ Jeffrey C. Smith |
| JEFFREY C. SMITH |
| Individually and as attorney-in-fact for Mark R. Mitchell, Peter A. Feld, Gavin T. Molinelli, Patrick Sullivan, and James P. Fogarty |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 24 of 26 – SEC Filing
SCHEDULE A
Transactions in the Shares Since the Filing of the Schedule 13D
| Nature of the Transaction | Amount of Securities Purchased/(Sold) | Price Per Share($) | Date of Purchase/Sale |
STARBOARD VALUE AND OPPORTUNITY MASTER FUND LTD
| Purchase of Common Stock | 32,843 | 14.9907 | 04/07/2016 |
| Purchase of Common Stock | 231,725 | 15.1026 | 04/07/2016 |
| Sale of Cash-Settled Total Return Swap | (231,725) | 15.0850 | 04/07/2016 |
| Purchase of Common Stock | 5,473 | 14.9907 | 04/07/2016 |
| Purchase of Common Stock | 38,448 | 15.1026 | 04/07/2016 |
| Sale of Cash-Settled Total Return Swap | (38,448) | 15.0850 | 04/07/2016 |
| Sale of Cash-Settled Total Return Swap | (264,828) | 16.8500 | 04/08/2016 |
| Purchase of Common Stock | 264,828 | 16.8392 | 04/08/2016 |
| Sale of Cash-Settled Total Return Swap | (43,941) | 16.8500 | 04/08/2016 |
| Purchase of Common Stock | 43,941 | 16.8392 | 04/08/2016 |
| Sale of Cash-Settled Total Return Swap | (198,621) | 16.5800 | 04/11/2016 |
| Purchase of Common Stock | 198,621 | 16.5673 | 04/11/2016 |
| Sale of Cash-Settled Total Return Swap | (32,956) | 16.5800 | 04/11/2016 |
| Purchase of Common Stock | 32,956 | 16.5673 | 04/11/2016 |
| Sale of Cash-Settled Total Return Swap | (264,828) | 15.7600 | 04/12/2016 |
| Purchase of Common Stock | 264,828 | 15.7509 | 04/12/2016 |
| Sale of Cash-Settled Total Return Swap | (43,941) | 15.7600 | 04/12/2016 |
| Purchase of Common Stock | 43,941 | 15.7509 | 04/12/2016 |
STARBOARD VALUE AND OPPORTUNITY S LLC
| Purchase of Common Stock | 3,958 | 14.9907 | 04/07/2016 |
| Purchase of Common Stock | 27,400 | 15.1026 | 04/07/2016 |
| Sale of Cash-Settled Total Return Swap | (27,400) | 15.0850 | 04/07/2016 |
| Purchase of Common Stock | 663 | 14.9907 | 04/07/2016 |
| Purchase of Common Stock | 4,549 | 15.1026 | 04/07/2016 |
| Sale of Cash-Settled Total Return Swap | (4,549) | 15.0850 | 04/07/2016 |
| Sale of Cash-Settled Total Return Swap | (31,314) | 16.8500 | 04/08/2016 |
| Purchase of Common Stock | 31,314 | 16.8392 | 04/08/2016 |
| Sale of Cash-Settled Total Return Swap | (5,199) | 16.8500 | 04/08/2016 |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 25 of 26 – SEC Filing
| Purchase of Common Stock | 5,199 | 16.8392 | 04/08/2016 |
| Sale of Cash-Settled Total Return Swap | (23,485) | 16.5800 | 04/11/2016 |
| Purchase of Common Stock | 23,485 | 16.5673 | 04/11/2016 |
| Sale of Cash-Settled Total Return Swap | (3,899) | 16.5800 | 04/11/2016 |
| Purchase of Common Stock | 3,899 | 16.5673 | 04/11/2016 |
| Sale of Cash-Settled Total Return Swap | (31,314) | 15.7600 | 04/12/2016 |
| Purchase of Common Stock | 31,314 | 15.7509 | 04/12/2016 |
| Sale of Cash-Settled Total Return Swap | (5,199) | 15.7600 | 04/12/2016 |
| Purchase of Common Stock | 5,199 | 15.7509 | 04/12/2016 |
STARBOARD VALUE AND OPPORTUNITY C LP
| Purchase of Common Stock | 2,175 | 14.9907 | 04/07/2016 |
| Purchase of Common Stock | 15,225 | 15.1026 | 04/07/2016 |
| Sale of Cash-Settled Total Return Swap | (15,225) | 15.0850 | 04/07/2016 |
| Purchase of Common Stock | 364 | 14.9907 | 04/07/2016 |
| Purchase of Common Stock | 2,503 | 15.1026 | 04/07/2016 |
| Sale of Cash-Settled Total Return Swap | (2,503) | 15.0850 | 04/07/2016 |
| Sale of Cash-Settled Total Return Swap | (17,400) | 16.8500 | 04/08/2016 |
| Purchase of Common Stock | 17,400 | 16.8392 | 04/08/2016 |
| Sale of Cash-Settled Total Return Swap | (2,860) | 16.8500 | 04/08/2016 |
| Purchase of Common Stock | 2,860 | 16.8392 | 04/08/2016 |
| Sale of Cash-Settled Total Return Swap | (2,145) | 16.5800 | 04/11/2016 |
| Purchase of Common Stock | 2,145 | 16.5673 | 04/11/2016 |
| Sale of Cash-Settled Total Return Swap | (13,051) | 16.5800 | 04/11/2016 |
| Purchase of Common Stock | 13,051 | 16.5673 | 04/11/2016 |
| Sale of Cash-Settled Total Return Swap | (17,400) | 15.7600 | 04/12/2016 |
| Purchase of Common Stock | 17,400 | 15.7509 | 04/12/2016 |
| Sale of Cash-Settled Total Return Swap | (2,860) | 15.7600 | 04/12/2016 |
| Purchase of Common Stock | 2,860 | 15.7509 | 04/12/2016 |
STARBOARD VALUE LP
(Through the Starboard Value LP Account)
| Purchase of Common Stock | 4,524 | 14.9907 | 04/07/2016 |
| Purchase of Common Stock | 30,150 | 15.1026 | 04/07/2016 |
| Sale of Cash-Settled Total Return Swap | (30,150) | 15.0850 | 04/07/2016 |
| Sale of Cash-Settled Total Return Swap | (34,458) | 16.8500 | 04/08/2016 |
| Purchase of Common Stock | 34,458 | 16.8392 | 04/08/2016 |
| Sale of Cash-Settled Total Return Swap | (25,843) | 16.5800 | 04/11/2016 |
| Purchase of Common Stock | 25,843 | 16.5673 | 04/11/2016 |
| Sale of Cash-Settled Total Return Swap | (34,458) | 15.7600 | 04/12/2016 |
| Purchase of Common Stock | 34,458 | 15.7509 | 04/12/2016 |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 26 of 26 – SEC Filing
JAMES P. FOGARTY
| Purchase of Common Stock | 16,450 | 15.1800 | 04/07/2016 |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
